Celltrion partners with Medidata to enhance clinical research programs for biosimilars

Korean biopharmaceutical company Celltrion announced it has adopted Medidata’s cloud-based technology platform, the Clinical Cloud, to enhance its research and development efforts.

“Celltrion is researching the therapeutic impact of large and complex molecules, which, by their very nature, involve numerous complicated clinical trials,” Sang-Joon Lee, Celltrion’s vice president, said in the press release. “This makes it even more important for us to have flexibility and simplicity in our research technology platforms. That is exactly what Medidata’s cloud-based technology will provide. We believe Medidata can help Celltrion in its effort to accelerate and expand access to advanced therapeutics for patients around the world.”

According to the release, Celltrion focuses on the research and manufacturing of biosimilars and other treatments for chronic diseases, including rheumatoid arthritis, cancer and respiratory diseases. The partnership will allow Celltrion to enhance its data management capabilities and increase the efficiency and accuracy of its clinical trials on biosimilars by implementing Medidata’s cloud-based technology for medical coding, trial supply management and electronic data capture.

“Our technology will provide Celltrion with unmatched visibility into the direction and success of its growing pipeline worldwide,” Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific region, said in the release. “The life sciences industry is rapidly growing in Asia, especially in the burgeoning field of biosimilars, and Medidata is excited to be partnering with a company like Celltrion that is at the forefront of this growth.”

Reference s :